Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1ALL patients IN THE study will BE treated with ocrelizumab
(D05218)		----1件: 13 💬
2Continued ocrelizumab
(D05218)		----1件: 13 💬
3Interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab
(D05218)		----1件: 13 💬
4Natalizumab/natalizumab-sztn, alemtuzumab, ocrelizumab, rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, cladribine, ofatumumab, ublituximab-xiiy, ocrelizumab and hyaluronidase-ocsq
(D05218)		1件: Natalizumab1件: Natalizumab 💬 1件: ITGA4 💬 15件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬1件: 13 💬
5Observation OF ocrelizumab AS treatment IN rrms patients
(D05218)		----1件: 13 💬
6Ocrelizumab
(D05218)		1件: Ocrelizumab1件: Ocrelizumab (D05218) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬4件: 11, 13, 46, 49 💬
7Ocrelizumab / rhumab 2h7
(D05218)		1件: Ocrelizumab1件: Ocrelizumab (D05218) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
8Ocrelizumab 300 MG
(D05218)		1件: Ocrelizumab1件: Ocrelizumab (D05218) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 13 💬
9Ocrelizumab 300MG
(D05218)		1件: Ocrelizumab1件: Ocrelizumab (D05218) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 13 💬
10Ocrelizumab 300MG/10 ML
(D05218)		1件: Ocrelizumab1件: Ocrelizumab (D05218) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 13 💬
11Ocrelizumab 300MG/10ML
(D05218)		1件: Ocrelizumab1件: Ocrelizumab (D05218) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 13 💬
12Ocrelizumab 500MG
(D05218)		1件: Ocrelizumab1件: Ocrelizumab (D05218) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 46 💬
13Ocrelizumab 600 MG
(D05218)		1件: Ocrelizumab1件: Ocrelizumab (D05218) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 13 💬
14Ocrelizumab AT home
(D05218)		1件: Ocrelizumab1件: Ocrelizumab (D05218) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 13 💬
15Ocrelizumab dose 1
(D05218)		1件: Ocrelizumab1件: Ocrelizumab (D05218) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 13 💬
16Ocrelizumab dose 2 and dose 3
(D05218)		1件: Ocrelizumab1件: Ocrelizumab (D05218) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 13 💬
17Ocrelizumab IV
(D05218)		1件: Ocrelizumab1件: Ocrelizumab (D05218) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 13 💬
18Ocrelizumab SC
(D05218)		1件: Ocrelizumab1件: Ocrelizumab (D05218) 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 💬1件: 13 💬
19Perfusion OF treatment ocrelizumab
(D05218)		----1件: 13 💬
20Short-course ocrelizumab
(D05218)		----1件: 13 💬